华恒生物688639 时间: 2025年6月10日星期二 68.90分综合得分 较强 趋势方向 主力成本分析 33.71 元 当日主力成本 33.89 元 5日主力成本 31.06 元 20日主力成本 29.77 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 短期压力位 次 32.60 短期支撑位 34.13 北向资金数据 持股量179.43万股 占流通比0.78% 昨日净买入0.94万股 昨日增仓比0.004% 5日增仓比0.03% 20日增仓比0.174% 跌停 0 技术面分析 34.13 中期压力位 28.05 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 ★光脚阴线★ 下跌信号 ★长上影★ 表明行情上档压力沉重,升势受阻 ★倒转锤头★ 可能见底回升 资金流数据 每股收益0.2元 营业利润0.55亿元 市盈率--- 销售毛利率24.308% 净利润49,138,959.43元 2025年6月10日星期二 68.90 较强 33.71； 33.89； 31.06； 29.77； 2025年06月10日的资金流向数据方面 主力 ...

Policy Developments - The Central Committee and State Council issued an opinion to improve the adjustment mechanism for the basic medical insurance drug catalog and to establish an innovative drug catalog for commercial health insurance [2] - The opinion aims to promote the sharing of high-quality medical resources and enhance the capacity of grassroots medical institutions [2] - The commercial health insurance sector is becoming a crucial lever for the high-quality development of commercial health insurance, helping to address the payment challenges for innovative drugs [3] Medical Device Approvals - DaAn Gene obtained a medical device registration certificate for six nucleic acid test kits for respiratory pathogens, expanding its product portfolio [5] - BGI Innovation received a medical device registration certificate for a human papillomavirus genotyping test kit, classified as Class III [6] - Shanghai Pharmaceuticals received approval for the production of Formoterol Fumarate inhalation solution, which is used for the maintenance treatment of chronic obstructive pulmonary disease [7] Corporate Transactions - Pilin Bio announced the resumption of trading after China National Pharmaceutical Group acquired 21.03% of its shares, changing the controlling shareholder [8] - China General Nuclear Power Corporation plans to inject 500 million yuan into its subsidiary for proton medical research and development [9] - Zhonghui Pharmaceutical completed two rounds of financing totaling nearly 50 million yuan, which will be used for the construction of a hollow microneedle medical device production base [10] Industry Developments - Dongxing Medical's subsidiary signed two contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan [11] Regulatory Alerts - Huahai Pharmaceutical received a warning letter from the FDA regarding its production facility, which may affect future ANDA applications but will not significantly impact current performance [12]

【SynBioCon】 获 悉，近日， 诺泰生物 （688076.SH）与 诺唯赞生物 （688105.SH）战略签约，合作 成立合资公司，共同推进双方在 合成生物学领域 的业务发展。 这是诺泰生物在小分子技术平台，多肽技术平台和寡核苷酸技术平台的基础上，拓展建设的 合成生物学技 术平台 。公司高度重视科技平台的建设和创新，通过学科交叉推行平台战略，实现产业升级，扩大公司在 医药产品的技术和生产优势，巩固和提升在细分领域的领先地位。 此次战略合作的达成，不仅是诺泰生物（688076.SH）与诺唯赞生物（688105.SH）在业务拓展和技术创新 方面的重要一步，也为整个生物科技行业带来了新的发展机遇。期待双方未来在合成生物学领域内的探索 不仅能在生物医药领域产生重大影响力，还可以在 动物保健 与 农业 等更多领域产能较强的影响力。 合资 公司由诺泰生物控股 。 生物合成是生物学研究的前沿领域，以生物酶作为催化剂为核心。与传统化学反应相比， 生物酶催化展现 出诸多显著优势，如绿色无害、安全性高、特异性极强以及原子经济性高等。 （ Source: 《生物革命：创新改变了经济、社会和人们的生活——麦肯锡全球研究院》（ ...

【SynBioCon】 获悉，近日，世界知识产权组织（WIPO）公布了 2025年全球奖30强名单 ，黄埔本 土企业 慕恩（广州）生物科技有限公司 （以下简称"慕恩生物"）凭借其在微生物资源开发与生物制造 领域的突破性成果成功入围。包括慕恩生物在内，本次共有6家中国企业入围30强，慕恩生物是唯一一 家广东企业。 据悉，WIPO全球奖自2022年设立，是目前 全球知识产权领域的最高奖项 ，旨在表彰企业在知识产权 布局、技术创新、社会价值创造上的卓越实力。今年，共有来自95个国家的780家企业参与竞争这一 知识产权领域"奥斯卡"，脱颖而出的慕恩生物成为该奖项设立以来，首家入围30强的黄埔企业。 建立全球最大商业菌种库，引领可持续农业发展 当前，新一轮科技革命和产业变革不断加剧，企业之间的竞争愈发成为知识产权的比拼。而每年评选一 次的WIPO全球奖，便主要关注 企业能否将知识产权转化为成功的商业运营、能否通过知识产权战略 实现业务增长、能否有助于实现联合国可持续发展目标 。 据WIPO中国微信公众号消息，本次入围30强的6家中国企业，分别是慕恩生物、上海邦邦机器人有限 公司、碳一新能源（杭州）有限责任公司、成都成华 ...

天然生物基因组编码海量的功能基因，这些基因在长期进化选择过程中，占据了广泛的序列空间，并发展 出精巧多样的功能活性，为生物体在复杂环境中的生存和繁衍提供了独特优势。 随着测序获得的生物序列累计达数十亿量级，这些潜在的功能基因也为生物制造和合成生物技术提供了基 因元件的"宝库"。然而，尽管天然基因具备极为丰富的功能和应用潜力，目前只有一小部分热门的功能基因 （如基因编辑工具酶）被高质量注释并构建了序列或结构模型。因此，基于序列、结构或深度学习的基因 挖掘和蛋白质设计方法无法拓展至复杂功能基因，限制了对高价值基因元件的挖掘与开发利用。 【SynBioCon】 获悉，针对上述问题 ， 北京大学定量生物学中心钱珑 团队 于近日推出了 一款面向 合成生物学元件挖掘与生物制造应用的大语言模型 SYMPLEX ， 该模型通过融合领域大语言模型训 练、合成生物专家知识对齐和大规模生物信息分析，实现了从海量文献中自动化挖掘功能基因元件并精准 推荐其工程化应用潜力。 此外， 团队 与 中科院深圳先进技术研究院娄春波研究员 合作，将 SYMPLEX 应用于 mRNA 疫苗生物制 造关键酶—— 加帽酶的挖掘 ，成功获得多种高性能新型 ...

Group 1 - Company Gongchuang Turf (605099.SH) stated that the impact of domestic football events on its operations and performance is minimal, as its main business of artificial turf has a low revenue contribution from domestic sports grass [1] - Company Anglikang (002940.SZ) confirmed that its innovative drug project ALK-N001 is still in Phase I clinical trials, indicating a long R&D cycle and significant investment [2] - Company Yiwei Lithium Energy (300014.SZ) plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international brand image [3] Group 2 - Company Chaohongji (002345.SZ) also intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to advance its global strategy and improve competitiveness [4] - Company Dexin Technology (603032.SH) clarified that its subsidiary's sales revenue from products used in solid-state battery production is less than 1% of total revenue, emphasizing its focus on quality service [5] - Company Changshan Pharmaceutical (300255.SZ) announced that its application for the marketing authorization of Aibennapeptide injection for type 2 diabetes has been accepted, but the approval timeline remains uncertain [6] Group 3 - Company Baili Electric (600468.SH) reported that its revenue from nuclear fusion-related business is currently minimal, accounting for less than 1% of total revenue [7] - Company Chutianlong (003040.SZ) is exploring digital currency projects but faces risks related to new technology development and commercial application [8] - Company Dongxing Medical (301290.SZ) signed contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan, enhancing its R&D capabilities [9] Group 4 - Company Maixinlin (688685.SH) announced that its subsidiary signed contracts for computing power services worth 1.184 billion yuan, expected to positively impact future performance [10] - Company Haichen Pharmaceutical (300584.SZ) reported that its solid-state battery-related business has not yet generated revenue, which does not significantly affect overall performance [11] - Company Filinger (603226.SH) is undergoing stock trading suspension for investigation due to significant price deviations from fundamentals [12] Group 5 - Company Zhongdian Port (001287.SZ) disclosed that the National Integrated Circuit Fund reduced its stake by 1%, now holding 8.97% of the company [13] - Company Huasheng Co., Ltd. (600156.SH) is planning to acquire 100% of Yixin Technology, leading to a stock suspension for up to 10 trading days [14] - Company Jianghuai Automobile reported a 3.52% year-on-year decline in May sales, with new energy vehicle sales down 57.81% [15] - Company Aonong Biological reported a 9.44% year-on-year increase in May pig sales, with a total of 156,200 pigs sold [16]

Policy Developments - The National Health Commission is promoting the implementation of the "Blood Fee Waiver, No Need to Run Once" policy, aiming for full compliance by the end of 2025 across all blood stations and medical institutions in the country [1] Drug and Device Approvals - LuKang Pharmaceutical announced that its subsidiary has received approval for the consistency evaluation of Cimetidine Injection, which is used to treat symptoms caused by excessive stomach acid [2] - Baiyunshan reported that its subsidiary has received a drug registration certificate for Tadalafil Tablets, which are primarily used to treat erectile dysfunction [3] - Fuyuan Pharmaceutical announced that its subsidiary has received a drug registration certificate for Bromhexine Hydrochloride Oral Solution, suitable for treating respiratory diseases related to mucus secretion or clearance [4] Capital Market Activities - Tianxing Medical's IPO on the Sci-Tech Innovation Board has been terminated due to the withdrawal of its sponsor [5] - NuoTai Bio and NuoWeiZan signed a strategic cooperation agreement for a synthetic biology project, planning to establish a joint biopharmaceutical company [6] Industry Events - A medical team in the UK is experimenting with processing healthy human feces into freeze-dried powder to help patients infected with superbugs, showing promising results [8] - Huazhong University of Science and Technology has opened the first brain-computer interface outpatient clinic in Central China, aiming to provide assessments and consultations for patients [9] - Kelong Pharmaceutical responded to accusations regarding its Ergotamine Capsules, clarifying that the product is classified as a dietary supplement rather than a drug [10] - Green Valley Pharmaceutical has halted production of the controversial drug Mannitol Sodium Capsules due to expired registration and ongoing scrutiny of its clinical trials [11] - Weili Zhibo Biotechnology has received approval from the China Securities Regulatory Commission for its IPO and the full circulation of its unlisted shares [12][14]

长江商报消息 ●长江商报记者 汪静 "成分之争"的风波演变成两大医美巨头间的攻防战，华熙生物（688363.SH）与巨子生物（02367.HK） 之争逐渐白热化。在这背后，"玻尿酸女王"赵燕的焦虑已跃然纸上。 同处医美行业，华熙生物与巨子生物的核心产品重组胶原蛋白与玻尿酸均为具有填充、修复功能的生物 材料。过去，凭借着玻尿酸这一明星成分，华熙生物赢得了业绩与股价的双丰收，也将创始人赵燕送上 了山东女首富的宝座。 随着重组胶原蛋白等新型成分的崛起，华熙生物遭到了上市以来最严峻的挑战——2024年营收同比下滑 11.61%至53.71亿元，净利润骤降70.59%至1.74亿元，核心业务板块收入锐减32.68%。而2024年，医美 新贵巨子生物的营收约55.39亿元，净利润约20.62亿元，双双大幅增长。 "我们正在经历的不是市场周期的简单波动，而是一场关乎企业生存逻辑的深刻变革。"在华熙生物2024 年财报发布后的董事会上，赵燕的发言掷地有声。 赵燕出生于1966年，毕业于华东师范大学生物系，毕业后曾留校担任助教。1988年，海南建省的浪潮 中，赵燕感到机遇来临，于是辞去教职，与其他三名想要创业的大学老师凑了50 ...

Group 1 - The green food industry chain in Yingshang District, Fuyang City, is projected to reach a total output value of 11 billion yuan in 2024, representing a year-on-year growth of 28.65% [1] - Yingshang District aims to implement a "double hundred billion" plan for the green food industry, accelerating the establishment of a green agricultural product supply base in the Yangtze River Delta [1] Group 2 - The company Tongfu Dajiankang has a daily production capacity of 12,500 nutritious meals, with plans to increase this to 60,000 meals and 300,000 pastries in the first phase [2] - The company sources most of its raw materials locally, benefiting local farmers, especially large-scale growers [2] - A smart dairy central factory project with a total investment of 3 billion yuan is set to begin trial production by the end of August 2024, with an expected annual output of 250,000 tons of dairy products [3] Group 3 - Jianuo Biotechnology has become a leading company in the production of functional nutritional gummy products, achieving nearly 100 million yuan in output value in 2024 [4] - The company has invested 1.2 billion yuan in a synthetic biology research and development project, aiming to collaborate with research institutions for high-end nutrient and biological product development [4] Group 4 - The Yingshang District plans to develop functional food sectors represented by Jianuo Biotechnology and Hengboshi, prepared dishes represented by Yurun and Tongfu Dajiankang, and deep processing of meat, eggs, and dairy represented by Huangshi and enzymes [5]

南京诺唯赞生物科技股份有限公司 关于自愿披露签订战略合作协议 证券代码：688105 证券简称：诺唯赞 公告编号：2025-024 暨拟设立合资公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 南京诺唯赞生物科技股份有限公司（以下简称"公司"）与江苏诺泰澳 赛诺生物制药股份有限公司（以下简称"诺泰生物"）近日于南京市签署《合成 生物学合作项目战略合作协议》（以下简称"《战略合作协议》"或"协议"）， 以合成生物学技术平台为基础，结合有机合成、化学工艺等交叉技术，共同推进 双方在合成生物学领域的技术进步和项目合作。 ? 公司拟与诺泰生物共同设立一家生物制药公司（以下简称"合资公司" 或"项目公司"，具体名称待定，以市场监督管理机关登记的最终名称为准）， 公司持股比例为 49%，诺泰生物持股比例为 51%，以此为平台开展后续合作与具 体业务工作。合作项目的具体投资规模、建设方案等事项将由双方另行约定并履 行内部审议程序，尚具有不确定性。 ? 本次《战略合作协议》签署暨拟对外投资事项无需提交公司董事 ...